Clinical Trials | August 18, 2022
Sanofi updates on amcenestrant clinical development program
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
MeitY will provide technical support for digitalisation of the Ayush Sector under the Ayush Grid project for a period of three years
Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces
The vaccine has been developed by the National Equine Research Center, Hisar (Haryana) in collaboration with the Indian Veterinary Research Institute, Izzatnagar (Bareilly)
Clinikk has raised $6.4 Million so far from marquee investors such as MassMutual Ventures, 500 Startups, Times Internet and prominent angels like Kunal Shah, Rohit MA, Rajan Anandan etc.
Subscribe To Our Newsletter & Stay Updated
